Roche’s Gazyva Recommended by CHMP for Adults With Active SLE

The EMA’s CHMP recommended Gazyva/Gazyvaro for adults with active SLE despite standard therapy. A European Commission decision is expected soon. In ALLEGORY, 76.7% achieved an SRI-4 response at week 52, versus 53.5% on placebo.